Overview

BMA vs Cortisone for Glenohumeral Osteoarthritis

Status:
Active, not recruiting

Trial end date:
2021-10-01

Target enrollment:
0

Participant gender:
All

Summary

This randomized trial seeks to investigate the difference if any between cortisone injection versus bone marrow aspirate injection in the glenohumeral joint of patients with confirmed osteoarthritis. The investigators hope that results from a prospective randomized controlled pilot study on bone marrow aspirate (BMA) glenohumeral joint (GHJ) injections will provide valuable early information on an alternative treatment for GHJ osteoarthritis (OA). This novel study will also contribute clinical data to the growing pool of research around BMA in the treatment of osteoarthritis. This study has the potential to uncover a new and more effective therapy to add to the arsenal of an orthopaedic surgeon in the management of GHJ OA. This would provide improved care and treatment for those disabled by GHJ OA. Additionally, this knowledge would be applicable to a variety of medical practitioners who treat GHJ OA from the general orthopaedic surgeon to pain subspecialists.

Phase:

Phase 2/Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Women's College Hospital

Collaborator:

University of Toronto

Treatments:

Cortisone
Cortisone acetate
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate

Criteria

Inclusion Criteria:

- Men or women above the age of 18 - 65

- Primary diagnosis of glenohumeral joint osteoarthritis (Samilson and Prieto Stage 1, 2
or 3)

- Provision of informed consent

Exclusion Criteria:

- Prior condition (such as trauma, avascular necrosis, fracture, iatrogenic or
chondrolysis) resulting in secondary osteoarthritis

- Previous surgical intervention for GHJ OA

- Previous injection of cortisone or other substance

- Inability to comply with rehabilitation or form completion

- Likely problems, in the judgement of the investigators, with maintaining follow-up
(i.e. patients with no fixed address, patients not mentally competent to give consent,
etc.)

- WSIB involvement

- Lawsuit involvement